Inspire Medical partners with Ognomy giving new hope to sleep apnea sufferers across the U.S., removing price and logistical barriers for those seeking diagnosis and treatment.
Buffalo, NY: April 29th – Ognomy, the complete sleep apnea care platform and app that launched in fall 2020, today announced the beginning of a new partnership with leading sleep apnea treatment innovator, Inspire Medical Solutions, bringing a potentially life saving offering to the estimated 25 million Americans suffering from the “not-so-silent killer”.
“We are thrilled to announce our strategic partnership with one of the largest and most respected companies in the sleep medicine space”, commented Dr. Daniel Rifkin, CEO, Ognomy. “Their investment in Ognomy further validates our mission to democratize access to the highest quality of sleep apnea care through an end-to-end virtual platform for both patient and provider.”
The multi-phase collaboration is part of Ognomy’s ambition to make sleep apnea testing and treatment accessible to anyone, at any time, by eliminating the need for multiple hospital referrals and repeated office visits. Through the integration, Inspire patients will have access to Ognomy’s roster of sleep medicine specialists and a self-administered sleep study that removes the need for disruptive clinic visits and overnight stays at a sleep laboratory. This allows patients to be quickly and easily evaluated for Inspire’s treatment solution which is an innovative alternative to CPAP for patients with moderate to severe obstructive sleep apnea.
“Positioning Ognomy’s diagnosis and testing offering together with Inspire’s treatment solution, allows us to extend the treatment options we give to our patients and greatly improve the lives of patients who may live in the remotest parts of the country.” says Dr. Rifkin, “but, most importantly, it allows us to empower patients to transform their sleep, health and wellness by tackling this prevalent sleep disorder, one of the most common under-diagnosed and under-treated chronic diseases, and its burden on population health.”
This partnership further enhances our journey to transform sleep apnea care and greatly improve the lives of patients across the U.S.
Ognomy, the vision of founder and CEO Daniel Rifkin, MD, a New York-based sleep medicine specialist, is a HIPAA compliant telemedicine platform and the only end-to-end solution providing remote access to full-lifecycle sleep apnea care. The start-up plans to quickly expand across America, and is already available in many states.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
About sleep apnea
Known as the “not-so-silent killer” due to its association with loud snoring, obstructive sleep apnea occurs when the muscles in the throat relax and close during sleep, which disrupts breathing. As a result, the body subconsciously wakes itself in an attempt to return breathing to normal. For many who suffer from sleep apnea, this pattern can be repeated hundreds of times in a single night. Left untreated, the sleep disorder can lead to a wide range of health complications, including increased risk of heart attack, high blood pressure, type 2 diabetes, liver problems, and accidents due to drowsiness or lack of concentration.
Ken Rosenfeld, Ognomy: firstname.lastname@example.org
Judy Kelleher, Ognomy: email@example.com